nav-left cat-right
cat-right

BIOSERVE and DNAPRINT(R) GENOMICS FORM STRATEGIC A...

BioServe’s fully annotated clinical samples across many diseases to be tagged with ancestry information using DNAPrint’s genetic ancestry tests BELTSVILLE, MD., Oct. 9, 2007 – BioServe today announced the formation of strategic alliance with DNAPrint® Genomics, Inc. (OTCBB: DNAG) to provide biomedical researchers with clinical DNA samples that for the first time will include genetic ancestry data for...

New compounds promising candidates for neurodegene...

Scientists have developed a novel strategy for tackling neurodegenerative diseases such as Huntington’s disease: encouraging an individual’s own cells to “eat” the malformed proteins that lead to the disease. Huntington’s disease is one of a number of degenerative diseases marked by clumps of malformed protein in brain cells. Symptoms include abnormal movements, psychiatric disturbances like...

Oxford International’s Clinical Trial Management...

Oxford International are pleased to announce the Clinical Trial Management Congress, to be held in Park Hyatt Hotel at the Bellevue, Philadelphia, USA on 6th – 7th November 2006. The congress offers attendees an unprecedented opportunity to network with leading senior-level clinical trials and technology executives, to identify successful strategies in maximising clinical trial productivity, through the application of...

GENFIT initiates Phase II clinical trials with GFT...

Phase I results revealed very good tolerance in healthy volunteers as well as an excellent security profile for GFT14, one of the medical candidates that GENFIT is developing to tackle cardiometabolic risk. Lille (France), Cambridge (Massachusetts), 2nd May 2006 – GENFIT, the biopharmaceutical company engaged in the discovery and development of medical candidates in the areas of cardiovascular, inflammatory and...
Page 8 of 8« First...45678